Zevra Therapeutics (ZVRA) EBT (2016 - 2025)
Historic EBT for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$977000.0.
- Zevra Therapeutics' EBT rose 9705.94% to -$977000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $53.6 million, marking a year-over-year increase of 15982.78%. This contributed to the annual value of -$90.1 million for FY2024, which is 9574.8% down from last year.
- Latest data reveals that Zevra Therapeutics reported EBT of -$977000.0 as of Q3 2025, which was up 9705.94% from $76.9 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' EBT ranged from a high of $76.9 million in Q2 2025 and a low of -$33.2 million during Q3 2024
- In the last 5 years, Zevra Therapeutics' EBT had a median value of -$10.2 million in 2023 and averaged -$4.7 million.
- As far as peak fluctuations go, Zevra Therapeutics' EBT skyrocketed by 62211.87% in 2021, and later tumbled by 65009.44% in 2024.
- Quarter analysis of 5 years shows Zevra Therapeutics' EBT stood at -$2.7 million in 2021, then surged by 342.38% to $6.5 million in 2022, then plummeted by 407.5% to -$19.9 million in 2023, then dropped by 2.39% to -$20.4 million in 2024, then skyrocketed by 95.2% to -$977000.0 in 2025.
- Its last three reported values are -$977000.0 in Q3 2025, $76.9 million for Q2 2025, and -$1.9 million during Q1 2025.